A Care Process Model to Deliver 177Lu-Dotatate Peptide Receptor Radionuclide Therapy for Patients With Neuroendocrine Tumors

MLA

Debora L. Aloszka, et al. “A Care Process Model to Deliver 177Lu-Dotatate Peptide Receptor Radionuclide Therapy for Patients With Neuroendocrine Tumors.” Frontiers in Oncology, vol. 8, Jan. 2019. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....b661c01f546f302386bcf20ed64bfc35&authtype=sso&custid=ns315887.

APA

Debora L. Aloszka, Akash Sharma, Catherine L. Maige, Faisal Shahjehan, Pashtoon Murtaza Kasi, Margaret L. Andrus, Manoj Kumar Jain, Jessica McMillan, Jessica M. Rodgers, Ashton Ritter, & Kabir Mody. (2019). A Care Process Model to Deliver 177Lu-Dotatate Peptide Receptor Radionuclide Therapy for Patients With Neuroendocrine Tumors. Frontiers in Oncology, 8.

Chicago

Debora L. Aloszka, Akash Sharma, Catherine L. Maige, Faisal Shahjehan, Pashtoon Murtaza Kasi, Margaret L. Andrus, Manoj Kumar Jain, et al. 2019. “A Care Process Model to Deliver 177Lu-Dotatate Peptide Receptor Radionuclide Therapy for Patients With Neuroendocrine Tumors.” Frontiers in Oncology 8 (January). http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....b661c01f546f302386bcf20ed64bfc35&authtype=sso&custid=ns315887.